MA32932B1 - Inhibiteurs de hsp90 utiles dans un traitement therapeutique - Google Patents

Inhibiteurs de hsp90 utiles dans un traitement therapeutique

Info

Publication number
MA32932B1
MA32932B1 MA33956A MA33956A MA32932B1 MA 32932 B1 MA32932 B1 MA 32932B1 MA 33956 A MA33956 A MA 33956A MA 33956 A MA33956 A MA 33956A MA 32932 B1 MA32932 B1 MA 32932B1
Authority
MA
Morocco
Prior art keywords
treatment
useful
hsp90 inhibitors
syndrome
castleman
Prior art date
Application number
MA33956A
Other languages
Arabic (ar)
English (en)
Inventor
Carlos Garcia-Echeverria
Michael Rugaard Jensen
Cornelia Quadt
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40139942&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32932(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA32932B1 publication Critical patent/MA32932B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'invention concerne l'utilisation d'un inhibiteur de Hsp90 dans le traitement du cancer de la vessie, du colon, du foie, du poumon, du sein, du vagin, des ovaires, du pancréas, du rein, de l'estomac, du tractus gastro-intestinal, de la prostate, de la tête et du cou, de la cavité péritonéale, de la thyroïde, des os, du cerveau, du système nerveux central et/ou de la leucémie et/ou dans le traitement du syndrome myélodysplasique, de la mastocytose systémique, du syndrome de Von Hippel-Lindau, de la maladie de Castleman multicentrique et/ou du psoriasis.
MA33956A 2008-11-28 2009-11-25 Inhibiteurs de hsp90 utiles dans un traitement therapeutique MA32932B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08170284 2008-11-28
PCT/EP2009/065862 WO2010060940A2 (fr) 2008-11-28 2009-11-25 Inhibiteurs de hsp90 utiles dans un traitement therapeutique

Publications (1)

Publication Number Publication Date
MA32932B1 true MA32932B1 (fr) 2012-01-02

Family

ID=40139942

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33956A MA32932B1 (fr) 2008-11-28 2009-11-25 Inhibiteurs de hsp90 utiles dans un traitement therapeutique

Country Status (16)

Country Link
US (2) US20110230499A1 (fr)
EP (2) EP2572709A1 (fr)
JP (1) JP2012510444A (fr)
KR (1) KR20110097907A (fr)
CN (1) CN102227220A (fr)
AU (1) AU2009319051A1 (fr)
BR (1) BRPI0924107A2 (fr)
CA (1) CA2743722A1 (fr)
IL (1) IL212924A0 (fr)
MA (1) MA32932B1 (fr)
MX (1) MX2011005664A (fr)
RU (1) RU2011126254A (fr)
TN (1) TN2011000240A1 (fr)
TW (1) TW201024295A (fr)
WO (1) WO2010060940A2 (fr)
ZA (1) ZA201103576B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2624493C2 (ru) * 2011-10-14 2017-07-04 Новартис Аг 2-КАРБОКСАМИД ЦИКЛОАМИНО ПРОИЗВОДНЫЕ МОЧЕВИНЫ В КОМБИНАЦИИ С ИНГИБИТОРАМИ Hsp90 ДЛЯ ЛЕЧЕНИЯ ПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
EP2972394A4 (fr) 2013-03-15 2016-11-02 Sloan Kettering Inst Cancer Imagerie cardiaque à ciblage hsp90 et traitement associé
GB201306610D0 (en) * 2013-04-11 2013-05-29 Almac Discovery Ltd Pharmaceutical compounds
US9840489B2 (en) 2013-12-20 2017-12-12 Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China Piperidine carboxamide compound, preparation method, and usage thereof
MX387627B (es) 2014-09-17 2025-03-18 Memorial Sloan Kettering Cancer Center Formación de imágenes de inflamación e infección dirigida a hsp90 y terapia
EP3558979B1 (fr) 2016-12-22 2021-02-17 Boehringer Ingelheim International GmbH Nouvelles quinazolines substituées benzylamino et dérivés en tant qu'inhibiteurs de sos1
HRP20230400T1 (hr) 2017-12-21 2023-06-23 Boehringer Ingelheim International Gmbh Benzilamino supstituirani piridopirimidinoni i derivati kao inhibitori sos1
CN118974051A (zh) * 2022-03-22 2024-11-15 上海维申医药有限公司 作为Toll样受体激动剂的嘧啶并哒嗪酮类化合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE526019T1 (de) * 2000-07-28 2011-10-15 Sloan Kettering Inst Cancer Verfahren zur behandlung von zellproliferationen störungen und virusinfektionen
JO2783B1 (en) * 2005-09-30 2014-03-15 نوفارتيس ايه جي Compounds 2-Amino-7, 8-dihydro-6H-Bayredo (3,4-D) Pyrimidine-5-Ones
MA32934B1 (fr) * 2008-11-28 2012-01-02 Novartis Ag Combinaisons inhibitrices hsp90

Also Published As

Publication number Publication date
TN2011000240A1 (en) 2012-12-17
TW201024295A (en) 2010-07-01
CN102227220A (zh) 2011-10-26
AU2009319051A1 (en) 2010-06-03
RU2011126254A (ru) 2013-01-10
BRPI0924107A2 (pt) 2019-09-24
JP2012510444A (ja) 2012-05-10
ZA201103576B (en) 2012-01-25
CA2743722A1 (fr) 2010-06-03
US20110230499A1 (en) 2011-09-22
IL212924A0 (en) 2011-07-31
WO2010060940A2 (fr) 2010-06-03
WO2010060940A3 (fr) 2010-08-26
MX2011005664A (es) 2011-06-16
KR20110097907A (ko) 2011-08-31
EP2572709A1 (fr) 2013-03-27
EP2370079A2 (fr) 2011-10-05
US20130045983A1 (en) 2013-02-21

Similar Documents

Publication Publication Date Title
MA32932B1 (fr) Inhibiteurs de hsp90 utiles dans un traitement therapeutique
CY2017013I2 (el) ΑΝΤΙΣΩΜΑ ΕΝΑΝΤΙΟΝ PDGFR-α ΓΙΑ ΧΡΗΣΗ ΣΤΗΝ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΟΓΚΩΝ
JP2010507577A5 (fr)
MY163477A (en) Pyrimidinyl-pyridazinone derivatives
NO20070951L (no) Inhibitorer av angiopoientinlignende-4-protein, kombinasjoner og deres anvendelse.
MY153198A (en) Inhibitors of protein aggregation
UA100540C2 (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
EA200901611A1 (ru) Производные 2-оксо-3-бензил-бензоксазол-2-она и родственные соединения в качестве ингибиторов мет киназы для лечения опухолей
TW200942552A (en) Combination therapy with c-Met and HER antagonists
UA104731C2 (ru) Ингибиторы р38 мар-киназ
UA87153C2 (ru) Энантиомерно чистые аминогетероарильные соединения как ингибиторы протеинкиназы
EA200901601A1 (ru) Производные пиридазинона
MX2010003368A (es) Derivados de imidazol.
EA201100334A1 (ru) Бициклические производные триазола для лечения опухолей
PL2259800T3 (pl) Zastosowanie 5-(2,6-dimorfolin-4-ylopirymidyn-4-ylo)-4-trifluorometylopirydyn-2-yloaminy do leczenia niedrobnokomórkowego raka płuca wykazującego nabytą oporność wobec modulatorów receptora dla naskórkowego czynnika wzrostu (EGFR)
EP2198296A4 (fr) Procédé d'utilisation de l'intégrité d'arn tumoral pour mesurer la réponse à la chimiothérapie chez des patients atteints de cancer
NO20071613L (no) Forbindelser for myokardial perfusjons-billeddannelse
MX2009010269A (es) Metodos de tratamiento del cancer mediante administracion de combinaciones de interleucina-18 humana.
NO20084892L (no) C-kit kinase inhibitor for anvendelse i terapeutisk behandling av gastrointestinal stromaltumor eller mastocytose.
EA200801430A1 (ru) Производные триазола
EP2630498A4 (fr) Biomarqueurs pronostiques chez des patientes atteintes d'un cancer ovarien
EA200901179A1 (ru) Замещённые тетрагидрохинолины
MX2010004259A (es) Tratamientos antitumorales mejorados.
BRPI0812924A2 (pt) Imunocitocinas para o tratamento de câncer em combinação com agentes quimioterapêuticos
EA200971067A1 (ru) Триазолиламинопиримидиновые соединения